Session » (0582–0608) SLE – Treatment Poster I

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0589

A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE

9:00AM-11:00AM: Abstract Number: 0603

Antiphospholipid Antibodies as Potential Predictors of Disease Severity and Poor Prognosis in Systemic Lupus Erythematosus Associated Thrombocytopeinia

9:00AM-11:00AM: Abstract Number: 0594

Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease

9:00AM-11:00AM: Abstract Number: 0607

CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained

9:00AM-11:00AM: Abstract Number: 0590

Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus

9:00AM-11:00AM: Abstract Number: 0591

Despite Dramatic Expansion of Approved Biologics in SLE, Unmet Needs Remain

9:00AM-11:00AM: Abstract Number: 0605

Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy

9:00AM-11:00AM: Abstract Number: 0596

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks

9:00AM-11:00AM: Abstract Number: 0602

Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0597

Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study

9:00AM-11:00AM: Abstract Number: 0608

Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study

9:00AM-11:00AM: Abstract Number: 0582

Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial

9:00AM-11:00AM: Abstract Number: 0600

Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline

9:00AM-11:00AM: Abstract Number: 0587

Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data

9:00AM-11:00AM: Abstract Number: 0604

Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments

9:00AM-11:00AM: Abstract Number: 0598

Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study

9:00AM-11:00AM: Abstract Number: 0588

Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry

9:00AM-11:00AM: Abstract Number: 0593

Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0592

Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)

9:00AM-11:00AM: Abstract Number: 0595

Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period

9:00AM-11:00AM: Abstract Number: 0606

Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0601

Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue

9:00AM-11:00AM: Abstract Number: 0599

Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes

9:00AM-11:00AM: Abstract Number: 0584

Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator

9:00AM-11:00AM: Abstract Number: 0585

The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 0586

Therapeutic Drug Monitoring of Azathioprine and Tacrolimus in SLE Pregnancies: Preliminary Results from the LEGACY Cohort

9:00AM-11:00AM: Abstract Number: 0583

Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients

« View all sessions from this meeting